{"generic":"Urofollitropin","drugs":["Bravelle","Fertinex","Urofollitropin"],"mono":{"0":{"id":"645535-s-0","title":"Generic Names","mono":"Urofollitropin"},"1":{"id":"645535-s-1","title":"Dosing and Indications","sub":{"0":{"id":"645535-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Assisted reproductive technology, In women who have previously received pituitary suppression:<\/b> initial dose, 225 international units SUBQ daily beginning cycle day 2 or 3; adjust dose based on ovarian response on day 5; do not adjust dose more often than every 2 days or by more than 75 to 150 international units per adjustment; continue until adequate follicular development, and then administer human chorionic gonadotropin; MAX dose, 450 international units\/day; MAX duration of treatment, 12 days in most cases<\/li><li><b>Assisted reproductive technology, In women who have previously received pituitary suppression:<\/b> (when administered together with menotropins) initial dose, urofollitropin 150 international units plus menotropins 75 international units SUBQ OR urofollitropin 75 international units plus menotropins 150 international units SUBQ daily beginning cycle day 2 or 3; adjust dose based on ovarian response on day 5; do not adjust dose more often than every 2 days or by more than 75 to 150 international units per adjustment; continue until adequate follicular development, and then administer human chorionic gonadotropin; MAX combined dose of urofollitropin and menotropins, 450 international units\/day; MAX duration of treatment, 12 days in most cases<\/li><li><b>Ovulation induction:<\/b> initial cycle, 150 international units IM or SUBQ daily for 5 days<\/li><li><b>Ovulation induction:<\/b> subsequent cycles, determine the starting dose based on history of ovarian response; base dose adjustments on clinical monitoring, including serum estradiol levels and vaginal ultrasound; do not adjust dose more often than every 2 days or by more than 75 to 150 international units per adjustment; MAX dose, 450 international units\/day; MAX duration of treatment, 12 days in most cases<\/li><\/ul>"},"1":{"id":"645535-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"645535-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Assisted reproductive technology, In women who have previously received pituitary suppression<\/li><li>Ovulation induction<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Hypogonadotropic hypogonadism<\/li><li>Luteal phase defect<\/li><\/ul>"}}},"3":{"id":"645535-s-3","title":"Contraindications\/Warnings","sub":[{"id":"645535-s-3-9","title":"Contraindications","mono":"<ul><li>endocrinopathies, non-gonadal (eg, disorders of thyroid, pituitary, adrenal glands), uncontrolled<\/li><li>hypersensitivity to urofollitropin or any component of the product<\/li><li>neoplasm of the reproductive tract and accessory organ, sex hormone-dependent<\/li><li>neoplasm of the pituitary gland or hypothalamus<\/li><li>ovarian cysts or enlargement, idiopathic and unassociated with polycystic ovary syndrome<\/li><li>pregnancy<\/li><li>primary ovarian failure, indicated by high levels of follicle-stimulating hormone<\/li><li>uterine bleeding, abnormal, idiopathic<\/li><\/ul>"},{"id":"645535-s-3-10","title":"Precautions","mono":"<ul><li>congenital malformations may occur<\/li><li>ectopic pregnancy may occur<\/li><li>gestations and births, multiple, may occur<\/li><li>hemoperitoneum may occur from ovarian cyst rupture<\/li><li>hypersensitivity reactions, including anaphylaxis, have been reported<\/li><li>neoplasm, ovarian (both benign and malignant) has been reported in women treated with multiple drug therapies for controlled ovarian stimulation<\/li><li>ovarian hyperstimulation syndrome (OHSS) may occur, sometimes serious and accompanied by pulmonary or vascular complications; monitoring recommended; discontinuation may be required<\/li><li>ovarian enlargement, abnormal, may occur; monitoring recommended; use lowest effective dose<\/li><li>ovarian torsion has been reported; may be in association with history of torsion or ovarian cysts, OHSS, pregnancy, previous abdominal surgery, or polycystic ovaries<\/li><li>pulmonary complications (eg, acute respiratory distress syndrome, atelectasis), serious, have been reported<\/li><li>spontaneous abortion may occur<\/li><li>thromboembolic events (eg, intravascular thrombosis, embolism), including fatalities, have been reported; increased risk in women with preexisting risk factors for thrombosis<\/li><\/ul>"},{"id":"645535-s-3-11","title":"Pregnancy Category","mono":"<ul><li>X (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"645535-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"645535-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal cramps (14%), Nausea (up to 8.7%)<\/li><li><b>Neurologic:<\/b>Headache (8.1% to 12.7%)<\/li><li><b>Reproductive:<\/b>Abnormal vaginal bleeding (up to 8.6%), Menopausal flushing (up to 5.7%), Multiple birth (28.6% to 66.7%), Pain, Post-retrieval (8%), Pain in pelvis (6.7%)<\/li><li><b>Respiratory:<\/b>Disorder of respiratory system (up to 5.7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction, Occlusion of artery<\/li><li><b>Hematologic:<\/b>Thromboembolic disorder, Thrombophlebitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>CVA - cerebrovascular accident due to cerebral artery occlusion<\/li><li><b>Reproductive:<\/b>Large ovary, Ovarian cancer, Ovarian hyperstimulation syndrome (5% to 11.4%), Torsion of ovary<\/li><li><b>Respiratory:<\/b>Acute respiratory distress syndrome, Atelectasis, Pulmonary embolism, Pulmonary infarction<\/li><\/ul>"},"6":{"id":"645535-s-6","title":"Drug Name Info","sub":{"0":{"id":"645535-s-6-17","title":"US Trade Names","mono":"<ul><li>Bravelle<\/li><li>Fertinex<\/li><\/ul>"},"2":{"id":"645535-s-6-19","title":"Class","mono":"<ul><li>Female Reproductive Agent<\/li><li>Human Follicle Stimulating Hormone<\/li><\/ul>"},"3":{"id":"645535-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"645535-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"645535-s-7","title":"Mechanism Of Action","mono":"Systemic: Urofollitropin contains follicle-stimulating hormone (FSH). The combination of FSH and luteinizing hormone (LH) stimulates follicular growth and maturation . Chorionic gonadotropin (hCG), whose actions are nearly identical to those of LH, is administered following urofollitropin treatment to mimic the naturally occurring surge of LH that triggers ovulation .<br\/>"},"9":{"id":"645535-s-9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/><ul><li>reconstitute with NS and gently swirl to mix; do not shake<\/li><li>use immediately after reconstitution<\/li><li>may be mixed with Menopur(R) in the same syringe<\/li><li>IM administration should be performed by a healthcare provider<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>reconstitute with NS and gently swirl to mix; do not shake<\/li><li>use immediately after reconstitution<\/li><li>may be mixed with Menopur(R) in the same syringe<\/li><li>administer subQ in the abdomen; alternate injection sites<\/li><\/ul><\/li><\/ul>"},"10":{"id":"645535-s-10","title":"Monitoring","mono":"<ul><li>follicular development is evidence of efficacy<\/li><li>serum estradiol levels during therapy<\/li><li>vaginal ultrasounds during therapy<\/li><li>ovarian hyperstimulation syndrome, signs and symptoms, during therapy and for at least 2 weeks after hCG administration<\/li><\/ul>"},"11":{"id":"645535-s-11","title":"How Supplied","mono":"<b>Bravelle<\/b><br\/>Injection Powder for Solution: 75 IU<br\/>"},"13":{"id":"645535-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to immediately report symptoms of ovarian hyperstimulation syndrome (OHSS) (eg, severe pelvic or stomach pain, sudden weight gain, swollen stomach, decreased urine).<\/li><li>Inform patient of increased potential for multiple gestations and births with use.<\/li><li>Tell patient to immediately report symptoms of serious pulmonary conditions (eg, acute respiratory distress syndrome) or thrombosis.<\/li><li>Side effects may include headache, abdominal pain, and injection site pain or inflammation.<\/li><li>Advise patient to report symptoms of OHSS, including respiratory problems and thrombosis.<\/li><li>Advise patient to report symptoms of ovarian torsion.<\/li><li>Tell patient to report symptoms of ectopic pregnancy or spontaneous abortion.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><li>Advise patient to call healthcare professional if a treatment is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}}}